Zyvox

Zyvox (linezolid)
Company: Pfizer
Disease: Gram-positive bacterial infections
Global 2013-14 sales: $1.35 billion
U.S. patent expiration date: May 2015

Pfizer's ($PFE) Zyvox revenues in the U.S. grew last year, but that may not be the case come its 2015 patent expiration. Currently the world's best-selling branded agent used to treat serious Gram-positive pathogens, Zyvox recorded a 1% revenue uptick in 2013 primarily due to increased demand in both the U.S. and Europe.

One generics maker has already presented a challenge: Last February, Apotex notified Pfizer that it had filed an ANDA with the FDA for a copy, asserting the invalidity of Zyvox's basic patent. The following month, the pharma giant hit back, filing an action against Apotex in district court for patent infringement. In December the action was settled, Pfizer said in its annual report.

For more:
Pfizer to pay $3.3M to settle Zyvox probe
FDA warns against imaging med, flags Zyvox interaction

-- Carly Helfand (email | Twitter)

Zyvox
Read more on

Suggested Articles

Drug pricing remains the pharma industry's top concern in 2020, execs said in a survey, as political threats continue from Washington, D.C.

Allergan updated its Botox marketing for chronic migraine by featuring strong women powering through their too-frequent migraine days.

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.